logo
  

Autoliv Announces Cost Cuts Mainly Within European Operations; Plans To Reduce Global Headcount

Autoliv, Inc. (ALV) said the company is accelerating global structural cost reductions, particularly within its European operations. The initiatives include a reduction of total direct and indirect workforce by up to 11%. Autoliv will simplify logistics and geographic footprint and plans to close several sites in Europe. The initiatives are expected to reduce up to 2,000 indirect positions globally. Of this, up to 1,000 are expected to be in Europe. The company expects the first headcount reductions to occur in 2023.

Autoliv also plans to reduce its global direct headcount. The company anticipates that this will lead to a reduction of around 6,000 positions globally, or around 11% of total direct workforce.

Autoliv expects to accrue a minor part of the total accrual in the second quarter of 2023. The company expects the initiatives to be fully implemented by 2025 and to have a pay-back time of 1-2 years.

Autoliv reiterated its 2023 outlook indications from April 21, 2023, of around 8.5-9.0% adjusted operating margin and operating cash flow of around $900 million. The company said its cost reduction actions support medium- and long-term financial targets.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT